Envista Holdings (0HV) AI Stock Analysis

1 Followers

Envista Holdings

(Frankfurt:0HV)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Diagnostics leadership and installed baseA leading diagnostics position supported by a large installed base can reinforce customer retention and create recurring opportunities across hardware, software, services, and upgrades. Share gains and an integrated workflow also strengthen Envista’s competitive position as practices adopt connected digital dentistry.

Negative Factors

China VBP pricing pressureChina’s upcoming value-based procurement changes create a structural pricing and margin challenge rather than a temporary demand fluctuation. Lower reimbursement-linked prices could reduce profitability in orthodontics and implants, require operating adaptation, and constrain the earnings contribution from an important geographic market.

Envista Holdings (0HV) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 3.95B
Dividend Yield: ―
Average Volume (3M): 1,700
Price to Earnings (P/E): 6.3
Beta (1Y): 0.73
Revenue Growth: 4.38%
EPS Growth: 3793.14%
Country: Germany
Employees: 12,000
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Instruments & Supplies

Envista Holdings Business Overview & Revenue Model

Company Description

Envista Holdings Corporation is an enterprise dedicated to the development and distribution of a comprehensive range of dental solutions. These offerings are crucial for the identification, therapeutic intervention, and preventative care of diverse o...

Envista Holdings Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:5.56%|Next Earnings Date:Feb 10, 2027

Earnings Call SentimentPositive

The call was broadly positive, supported by solid third-quarter sales and earnings growth, margin expansion, strong cash flow, a raised full-year outlook, share gains in diagnostics and Spark, and continued operational and innovation progress. The main challenges were a soft U.S. market, weaker elective categories, China destocking and upcoming VBP pricing pressure, plus an implied slight fourth-quarter core sales decline and foreign exchange headwinds. Overall, the positive operating and financial trends significantly outweighed the stated challenges.

Positive Updates

Strong Third-Quarter Earnings Growth

Third-quarter sales were $691 million, up $21 million year over year, with core sales growth of 2.7% and total growth of 3.2%. Adjusted EBITDA increased 9% to approximately $106 million, adjusted EPS rose 25% to $0.40, and adjusted EBITDA margin expanded 80 basis points to 15.3%.

Negative Updates

Soft U.S. Dental Market and Macro Uncertainty

The U.S. dental market remains soft, with macroeconomic uncertainty affecting patient and clinician confidence. Management said macro uncertainty remains high and is expected to continue in the fourth quarter.

Company Guidance

Envista raised and narrowed its full year 2026 guidance to core sales growth of 3.75% to 4.25%, adjusted EBITDA growth of 12.5% to 14% and adjusted EPS of $1.54 to $1.58, compared with prior ranges of 3.5% to 4.5% and $1.50 to $1.55, with adjusted EPS up more than 10% at the midpoint from the initial 2026 guide; it continues to expect free cash flow conversion of approximately 100% for the full year and a full year tax rate of around 25.5% of adjusted pretax income, while fourth quarter guidance implies slightly negative core sales growth, or growth consistent with the full year range excluding 4 fewer selling days, with foreign exchange expected to reduce reported fourth quarter revenue growth by approximately 1 percentage point, acquisitions contributing approximately 0.5 percentage point, no significant VBP-related impact in the fourth quarter, and VBP implementation most likely to commence in the first half of 2027.

Envista Holdings Risk Analysis

Envista Holdings disclosed 48 risk factors in its most recent earnings report. Envista Holdings reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk

1.The conflict between the United States, Israel and Iran and related geopolitical instability may adversely affect our business.Q1, 2026

Envista Holdings Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:0HV against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MMSI	71Outperform	$5.28B	32.16	9.65%	―	9.34%	33.77%
PDEX	71Outperform	$228.77M	18.39	26.18%	―	13.31%	9.26%
MDLN	65Neutral	$55.47B	60.05	4.97%	―	11.85%	-57.19%
BDX	63Neutral	$58.43B	51.85	4.64%	1.84%	-7.40%	-28.89%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XRAY	50Neutral	$1.93B	-15.26	-9.02%	6.93%	-1.35%	86.31%

* Healthcare Sector Average

Performance Comparison

DE:0HV and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:0HV	Envista Holdings	22.80	5.90	34.91%
BDX	Becton, Dickinson and Co	215.71	67.71	45.75%
XRAY	DENTSPLY SIRONA	9.24	-1.13	-10.89%
MMSI	Merit Medical	86.69	1.60	1.88%
PDEX	Pro-dex	67.42	35.33	110.10%
MDLN	Medline, Inc. Class A	39.98	-1.02	-2.49%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Envista Holdings AI Stock Analysis